Quest Diagnostics Inc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Quest Diagnostics Inc (DGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.00% for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2017-02-22
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2014 was 2.00%, a 53.85% increase from fiscal 2013.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 1.30%, a 13.33% decline from fiscal 2012.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2012 was 1.50%, a 51.61% decline from fiscal 2011.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2011 was 3.10%, a 3.13% decline from fiscal 2010.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2014-12-31 | 2.00% 10-K · filed 2017-02-22 |
| 2013-12-31 | 1.30% 10-K · filed 2016-02-26 |
| 2012-12-31 | 1.50% 10-K · filed 2015-02-24 |
| 2011-12-31 | 3.10% 10-K · filed 2014-02-18 |
| 2010-12-31 | 3.20% 10-K · filed 2013-02-27 |
| 2009-12-31 | 2.30% 10-K · filed 2012-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |